Treatments that target amyloid plaques in Alzheimer's disease patients may also be useful for reducing tau tangles, according to two small studies presented here.
One study, a pooled analysis of two randomized trials in 46 Alzheimer's patients, found that bapineuzumab significantly reduced total and phospho-tau in cerebrospinal fluid compared with placebo after one year, according to Kaj Blennow, MD, PhD, of the University of Goteborg in Sweden, and colleagues.
In the other study, conducted among 38 people, the Alzheimer's vaccine known as AN1792 -- a trial of which was halted earlier in the decade due to brain swelling -- was associated with reduced tau deposits in the cerebral cortex and hippocampus, Delphine Boche, MD, of the University of Southampton in England, and colleagues reported.
Both groups presented their findings at the International Conference on Alzheimer's disease in Honolulu.
Continue Reading
No comments:
Post a Comment